On 31 May 2024, the European Medicines Agency (EMA) published the Committee for Medicinal Products for Human Use (CHMP) reflection paper on Creutzfeldt-Jakob disease (CJD) and plasma-derived and urine-derived medicinal products.
In a concerted effort to combat healthcare-associated infections (HAIs) and antimicrobial resistance (AMR), the European Centre for Disease Prevention and Control (ECDC) and the Belgian EU Presidency on 6-7 May co-hosted a conference at the national public health institute of Belgium, Sciensano, in Brussels.